



Let our proteins power your next discovery.



## History

The Institute for Protein Innovation (IPI) is the brainchild of scientist and entrepreneur Timothy Springer, the Latham Family Professor of Biological Chemistry and Molecular Pharmacology in the Blavatnik Institute at Harvard Medical School and Boston Children's Hospital.

Springer teamed up with co-founder Andrew Kruse, a professor at Harvard Medical School and expert on synthetic antibodies, to launch IPI in 2017 as a nonprofit institute. The pair aimed to create a means for basic research scientists to access antibodies directed against cell surface and secreted proteins, the key targets for most successful drugs.

In 2018, the Institute moved to the Harvard Institutes of Medicine in the heart of the Boston Longwood Medical and Academic Area. That same year, IPI launched its first campaign to help scientists validate their antibodies using high-throughput technology.

In 2021, IPI's board of directors, previously led by Springer, elected a new chair, Samantha Singer, formerly an entrepreneur-in-residence at Third Rock Ventures and now president and CEO of Abata Therapeutics. Singer brings these experiences, as well as her time as chief operating officer of the Broad Institute, to help IPI realize its vision as an academic-industry hybrid institute dedicated to accelerating biomedical research.

Kenneth Fasman, formerly senior vice president for research at The Jackson Laboratory, joined IPI as president and CEO in 2022. Beginning his career in computational neuroscience, Fasman designed and implemented the original Human Genome Project database at the Johns Hopkins School of Medicine. He then pivoted to bioinformatics, drug discovery and research strategy, spending more than three decades with top pharmaceutical companies and nonprofit genomics institutes. Under his guidance, IPI takes on a three-fold mission to build resources, aid research and empower education within the protein science and biological research communities.

Today, IPI remains an independent nonprofit research institute, partnering with researchers at Harvard Medical School, Boston Children's Hospital and more. Aligned with Springer's founding vision, IPI seeks to use protein tools and resources to impact biological research and ultimately, improve human health.



*Celebrating the launch of IPI in 2017. Photo courtesy of the Springer Lab*



*IPI co-founders Timothy Springer, left, and Andrew Kruse, right. Photo courtesy of the Springer Lab*